Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30<sup>+</sup> lymphoma patients.

导出 OA

翻译打印收藏纠错

作者： D,Wang ^[1] ; C,Zeng ^[1] ; B,Xu ^[1] ; J-H,Xu ^[1] ; J,Wang ^[1] ; L-J,Jiang ^[1] ; Q-X,Wang ^[1] ; C-R,Li ^[1] ; N,Wang ^[1] ; L,Huang ^[1] ; Y-C,Zhang ^[1] ; Y,Xiao ^[2] ; J-F,Zhou ^[3]

作者单位： Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P.R. China. ^[1] Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P.R. China. yixiao@tjh.tjmu.edu.cn. ^[2] Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P.R. China. jfzhou@tjh.tjmu.edu.cn. ^[3]

主题词人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);淋巴瘤(Lymphoma)

DOI 10.1038/s41408-020-0274-9

PMID 31974371

发布时间 2021-01-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交